METAP2 and prostate cancer: Both in vitro and in vivo studies demonstrated that these AUTOTACs (e.g., PBA-1105, Anle138b-F105, shown in Figure 7C) effectively targets the androgen receptor (AR) in prostate cancer cells and methionine aminopeptidase 2 (MetAP2) in glioblastoma cells, showcasing its powerful degradation capabilities (Ji et al., 2022).